In a small‐scale prospective study, osimertinib showed 50% ORR with median progression‐free survival (mPFS) of 8.2 months in 37 advanced NSCLC patients with uncommon EGFR mutations [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.